Efficacy of Bone Marrow-Derived Mesenchymal Stem Cells in the Treatment of Sclerodermatous Chronic Graft-versus-Host Disease: Clinical Report

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 3, 2010, Pages 403-412

  Zhou, Hong ^a   Guo, Mei ^b   Bian, Chunjing ^a   Sun, Zhao ^a   Yang, Zhuo ^a   Zeng, Yang ^a   Ai, HuiSheng ^b   Zhao, Robert Chunhua ^a  

^a Center of Excellence in Tissue Engineering   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Allogeneic hematopoietic cell transplantation; Bone marrow derived mesenchymal stem cell; Chronic graft versus host disease; Sclerodermatous chronic graft versus host disease

Indexed keywords

CYCLOSPORIN; PREDNISONE; TACROLIMUS; THALIDOMIDE;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CASE REPORT; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HELPER CELL; HUMAN; LABORATORY TEST; LEUKEMIA; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; RECURRENT DISEASE; SCLERODERMA; SKIN BIOPSY; SLERODERMATOUS CHRONIC GRAFT VERSUS HOST DISEASE; SURVIVAL RATE; TH1 CELL; TH2 CELL; VITAL SIGN;

ADIPOCYTES; ADULT; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHONDROCYTES; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOPHENOTYPING; INTERFERON-GAMMA; INTERLEUKINS; LYMPHOCYTE COUNT; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; OSTEOBLASTS; SCLERODERMA, LOCALIZED; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; TH1 CELLS; TH2 CELLS; TREATMENT OUTCOME;

EID: 75949085506     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.11.006     Document Type: Article

References (36)

1. Sullivan K.M., Shulman H.M., Storb R., et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 57 (1981) 267-276
2. Kim J., Choi W.S., Kim H.J., et al. Prevention of chronic graft-versus-host disease by stimulation with glucocorticoid-induced TNF receptor. Exp Mol Med 38 (2006) 94-99
3. Nagler A., Pines M., Abadi U., et al. Oral tolerization ameliorates liver disorders associated with chronic graft versus host disease in mice. Hepatology 31 (2000) 641-648
4. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease, I: Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant 11 (2005) 945-956
5. Cho B.S., Min C.K., Eom K.S., et al. Feasibility of NIH consensus criteria for chronic graft-versus-host disease. Leukemia 23 (2009) 78-84
6. Peñas P.F., Jones-Caballero M., Aragüés M., et al. Sclerodermatous graft-vs-host disease: clinical and pathological study of 17 patients. Arch Dermatol 138 (2002) 924-934
7. Vogelsang G.B., Wolff D., Altomonte V., et al. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA). Bone Marrow Transplant 17 (1996) 1061-1067
8. Krijanovski O.I., Hill G.R., Cooke K.R., et al. Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease. Blood 94 (1999) 825-831
9. Edwards J.C., and Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatol 40 (2001) 205-211
10. von Bonin M., Oelschlägel U., Radke J., et al. Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab. Transplantation 86 (2008) 875-879
11. Marcellus D.C., Altomonte V.L., Farmer E.R., et al. Etretinate therapy for refractory sclerodermatous chronic graft-versus-host disease. Blood 93 (1999) 66-70
12. Baudard M., Vincent A., Moreau P., et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients. Bone Marrow Transplant 30 (2002) 287-295
13. Skert C., Patriarca F., Sperotto A., et al. Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome. Haematologica 91 (2006) 258-261
14. Aggarwal S., and Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105 (2005) 1815-1822
15. Bartholomew A., Sturgeon C., Siatskas M., et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30 (2002) 42-48
16. Deng W., Han Q., Liao L., et al. Effects of allogeneic bone marrow-derived mesenchymal stem cells on T and B lymphocytes from BXSB mice. DNA Cell Biol 24 (2005) 458-463
17. Le Blanc K., Rasmusson I., Sundberg B., et al. Treatment of severe acute graft-versus-host disease with third-party haploidentical mesenchymal stem cells. Lancet 363 (2004) 1439-1441
18. Lazarus H.M., Koc O.N., Devine S.M., et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 11 (2005) 389-398
19. Ringdén O., Uzunel M., Rasmusson I., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81 (2006) 1390-1397
20. von Bonin M., Stölzel F., Goedecke A., et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 43 (2009) 245-251
21. Guo H., Fang B., Liao L., et al. Hemangioblastic characteristics of fetal bone marrow-derived Flk1(+)CD31(-) CD34(-) cells. Exp Hematol 31 (2003) 650-658
22. Zhang W., Ge W., Li C., et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev 13 (2004) 263-271
23. Clements P., Lachenbruch P., Siebold J., et al. Inter- and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 22 (1995) 1281-1285
24. Masubuchi Y., Sugiyama S., and Horie T. Th1/Th2 cytokine balance as a determinant of acetaminophen-induced liver injury. Chem Biol Interact 179 (2009) 273-279
25. Guo H., Qiao Z., Zhu L., et al. Th1/Th2 cytokine profiles and their relationship to clinical features in patients following nonmyeloablative allogeneic stem cell transplantation. Am J Hematol 75 (2004) 78-83
26. Shao D.D., Suresh R., Vakil V., et al. Pivotal advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation. J Leukoc Biol 83 (2008) 1323-1333
27. Darvay A., Salooja N., and Russell-Jones R. The effect of extracorporeal photopheresis on intracellular cytokine expression in chronic cutaneous graft-versus-host disease. J Eur Acad Dermatol Venereol 18 (2004) 279-284
28. Deng W., Han Q., Liao L., et al. Allogeneic bone marrow-derived flk-1 + Sca-1- mesnchymal stem cells leads to stable mixed chimerism and donor-specific tolerance. Exp Hematol 32 (2004) 861-867
29. Fang B., Shi M., Liao L., et al. Systemic infusion of Flk1+ mesenchymal stem cells ameliorate carbon tetrachloride-induced liver fibrosis in mice. Transplantation 78 (2004) 83-88
30. Yan X., Liu Y., Han Q., et al. Injured microenvironment directly guides the differentiation of engrafted Flk1+ mesenchymal stem cell in lung. Exp Hematol 35 (2007) 1466-1475
31. Liu L., Sun Z., Chen B., et al. Ex vivo expansion and in vivo infusion of bone marrow-derived Flk-1 + CD31-CD34- mesenchymal stem cells: feasibility and safety from monkey to human. Stem Cells Dev 15 (2006) 349-357
32. Guo M., Sun Z., Sun Q.Y., et al. A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia: successful engraftment and mild GVHD. Biol Blood Marrow Transplant 15 (2009) 930-937
33. Gao J., Dennis J.E., Muzic R.F., et al. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 169 (2001) 12-20
34. Zhao Z., Liao L., Cao Y., et al. Establishment and properties of fetal dermis-derived mesenchymal stem cell lines: plasticity in vitro and hematopoietic protection in vivo. Bone Marrow Transplant 36 (2005) 355-365
35. Ning H., Yang F., Jiang M., et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 22 (2008) 593-599
36. Miflin G., Russell N.H., Franklin I., et al. An analysis of the effect of chronic graft-versus-host disease on relapse and survival following allogenic peripheral blood stem cell transplantation. Cytotherapy 2 (2000) 423-428